U2AF1 mutations are heterozygous and are associated with adverse prognosis, increased risk of progression to AML, and poor overall survival (OS) in MDS and MPN patients [5], with U2AF1Q157 having a worse OS than U2AF1S34 [6]. Here, U2AF1 is linked to myeloproliferative neoplasm.